^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

Published date:
09/01/2023
Excerpt:
The median PFS (11.0 vs. 6.9 months) and ORR (66.7% vs. 60.0%) for patients with RAS/BRAF wild-type were numerically better than those with mutation….Anlotinib plus XELOX as first-line therapy in patients with mCRC showed anti-tumor activity and safety profile, which is worth further investigation.
Secondary therapy:
CAPOX
DOI:
https://doi.org/10.3389/fonc.2023.1238553
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

Published date:
01/17/2023
Excerpt:
RAS/BRAF wild-type unresectable mCRC patients with no prior systemic treatment received anlotinib...The ORR was 76.7% (95% CI, 57.7-90.1%) with 2 patient achieved a complete response (CR); DCR was 93.3% (95% CI, 77.9-99.2%). At the data cutoff date, the median DOR was 7.9 months (95% CI, 4.3–11.4) and the median DOT was 8.38 months (95%CI, 5.9-10.9)...Anlotinib combined with CAPEOX exhibited promising ORR in the first-line treatment of mCRC compared to those of previous treatment.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.3_suppl.138
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy

Published date:
05/06/2022
Excerpt:
Patients aged 18-75 with RAS/BRAF wild-type unresectable mCRC...The primary endpoint of ORR was 76.7% (95% CI, 57.7-90.1) with 1 patient achieving a complete response and 22 patients partial response. DCR was 93.3% (95% CI, 77.9-99.2). At a median follow-up of 14.1 months (95% CI, 9.9-18.3), median PFS was 11.3 months (95% CI, 7.1-14.1), and DOR was 7.9 months (95% CI, 5.5-12.7). Anlotinib combined with capecitabine and oxaliplatin showed considerable ORR, DCR, PFS, and DOR in the first-line therapy of mCRC...
Secondary therapy:
capecitabine + oxaliplatin
DOI:
10.1186/s12916-022-02357-6
Trial ID: